NL-OMON37839尚未招募3 期
A Phase 3b, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Study to Evaluate the Effect of Dalcetrapib 600 mg on Cardiovascular (CV) Events in Adult Patients with Stable Coronary Heart Disease (CHD), CHD Risk Equivalents or at Elevated Risk for Cardiovascular Disease (CVD). - dal-OUTCOMES 2
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 740
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Male and female patients at least 45 years of age with stable CHD, CHD risk equivalents or at elevated risk for CVD defined as the documented presence of at least one criterion in the categories A to D or at least 3 criteria in category E:;Patients with established CVD:;A. Stable coronary heart disease (CHD):
- •Prior myocardial infarction (> 3 months prior to randomization)
- •Prior coronary revascularization (PCI or CABG) (> 3 months prior to randomization)
- •Angiographic or CT-imaging (e.g., MDCT/CTA) evidence of coronary atherosclerosis (> 70% stenosis in at least one major epicardial coronary artery);B. Cerebrovascular disease:
- •Prior ischemic stroke (> 3 months prior to randomization) confirmed by a brain imaging study -
- •CT or MRI; thought not to be caused by atrial fibrillation, valvular heart disease or mural thrombus
- •Carotid artery stenosis > 70% on prior angiography or ultrasound
- •History of prior percutaneous or surgical carotid artery revascularization (> 3 months prior to randomization);C. Peripheral arterial disease (PAD):
- •Prior documentation of a resting ankle-brachial index <= 0.85
- •History of prior percutaneous or surgical revascularization of an iliac, femoral, or popliteal artery
- •(> 3 months prior to randomization)
- •Prior non-traumatic amputation of a lower extremity (> 3 months prior to randomization) due to peripheral artery disease;Patients without established CVD:;D. Patients with pharmacologically treated type 2 diabetes and one or more additional risk factor for
- •Age at least 70 years
- •History of type 2 diabetes at least15 years
- •eGFR at least 30 and max 60 ml/min/1.73m2 using the MDRD formula within 1 year prior to randomization
- •Albuminuria defined as spot urine albumin to creatinine ratio (ACR) at least 30 µg albumin /mg creatinine within 1 year prior to randomization;E. Patients with 3 or more of the following risk factors for CVD but without T2D:
- •HDL-C < 40 mg/dL (1.03 mmol/L) for men; < 50 mg/dL (1.29 mmol/L) for women within 1 year prior to randomization
- •Waist circumference at least 94 cm (men) at least 80 cm (women); at least 90 cm (men) at least 80 cm (women) for Asians and patients of Asian descent within 1 year prior to randomization
- •Hypertension: persistent elevated SBP at least 140 mmHG and/or DBP at least 90 mmHG despite treatment for hypertension
- •Family history of premature CHD (symptomatic CHD in male first degree relative < 55 years or in female first degree relative < 65 years. Symptomatic CHD defined as myocardial infarction or coronary revascularization)
- •Albuminuria defined as spot urine albumin to creatinine ratio (ACR) at least 30 µg albumin /mg creatinine within 1 year prior to randomization
- •eGFR at least 30 and max 60 ml/min/1.73m2 using the MDRD formula within 1 year prior to randomization
- •Current cigarette smoking;Appropriate documentation may include mention of the diagnosis in a discharge letter or in the patient*s file.;2. Within 6 months prior to randomization, evidence of guidelines-based management of LDL-C, at a minimum to include medical and dietary treatment to a level of LDL-C <100 mg/dL (2.6 mmol/L). Patients may be randomized if they cannot reach the goal of LDL-C < 100 mg/dL despite an
- •intensive statin / LDL-C lowering drug regimen (comprising of a maximum tolerated dose of statin as determined by the investigator) or are unable to tolerate stat
排除标准
- •1. Occurrence of myocardial infarction, hospitalization for unstable angina, stroke or revascularization (coronary, carotid or peripheral) within three months prior to randomization.
- •2. Planned revascularization (coronary, carotid or peripheral) after randomization.
- •3. Sustained systolic blood pressure > 180 mmHg and/or diastolic blood pressure > 110 mmHg.
- •4. Symptomatic congestive heart failure (NYHA Class III or IV).
- •5. Known left ventricular ejection fraction < 25%.
- •6. Presence of any of the following laboratory abnormality assessed within 6 months prior to randomization:
- •a. Triglycerides at least 400 mg/dL (4.5 mmol/L),
- •b. Hepatic transaminase > 2 x ULN or alkaline phosphatase levels > 2 x ULN or total bilirubin level > 1.5 x ULN
- •c. Creatine phosphokinase levels > 3 x ULN
- •d. eGFR < 30 ml/min/1.73m2 using the MDRD formula
- •e. or any laboratory abnormality that is considered to be clinically important by the investigator.
- •7. Known HbA1c > 10%
- •8. Known Hb < 8 g/dL
- •9. Current or previous (within 3 months prior to randomization) treatment with niacin, fibrates, bile acid sequestrants or drugs other than dalcetrapib administered for increasing HDL-C (treatment with ezetimibe, fish oil derivatives and multivitamins containing nicotinic acid (vitamin B3) is permitted).
- •10. Previous treatment with compounds targeting CETP, e.g. torcetrapib, anacetrapib or dalcetrapib.
- •11. Known or suspected intolerance or hypersensitivity to lactose.
- •12. Patients with clinically apparent liver disease, eg, jaundice, cholestasis, or active hepatitis.
- •13. History of malignancy (except for curatively treated basal cell or squamous cell carcinoma of the skin) during the 3 years prior to randomization.
- •14. Any clinically significant medical condition that according to the investigator could interfere with the conduct of the study or life expectancy shorter than the duration of the trial.
- •15. Current alcohol or drug abuse or history thereof within 5 years prior to randomization.
- •16. Patients who have received any investigational drug or device within 1 month prior to randomization, or who are expected to participate in any other investigational drug or device study during the conduct of this trial.
- •17. Women who are pregnant or breast-feeding.
- •18. Women of childbearing potential who are not using a highly effective contraceptive method at randomization (see protocol section 4.2.2).
- •19. Unable or unwilling to comply with protocol requirements throughout the duration of the trial (approximately 4 to 5 years follow-up), or deemed by the investigator to be unfit for the study.
研究者
相似试验
进行中（未招募）
1 期
A study evaluating the efficacy and safety of Etrasimod in the treatment of patients with moderately to severely active Ulcerative Colitislcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856MedDRA version: 20.1Level: LLTClassification code 10045366Term: Ulcerative colitis, unspecifiedSystem Organ Class: 100000004856EUCTR2018-003985-15-PTArena Pharmaceuticals Inc.433
进行中（未招募）
1 期
A study to test efficacy and safety of rozanolixizumab in adult patients with generalized myasthenia gravisEUCTR2019-000968-18-CZCB Biopharma SR240
进行中（未招募）
1 期
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based ChemotherapyHomologous recombination deficiency advanced ovarian cancerMedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-000952-11-ITTESARO, INCORPORATED733
进行中（未招募）
1 期
A Clinical trial to evaluate safety, and effectiveness of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)EUCTR2016-004148-13-PTGilead Sciences, Inc.800
招募中
1 期
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants with Advanced/Metastatic Non-Small Cell Lung Cancerung Cancer, Non-Small CellMedDRA version: 21.1Level: PTClassification code: 10029521Term: Non-small cell lung cancer stage IIIB Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10029522Term: Non-small cell lung cancer stage IV Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10061873Term: Non-small cell lung cancer Class: 100000004864CTIS2023-508443-40-00Glaxosmithkline Research & Development Limited644